Lomedeucitinib vs TQH3906
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
Lomedeucitinib
Developed by Beeline Medicines under a licence from Bristol-Myers Squibb
NCT05730725 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 109 participants, but each treatment group was relatively small. The clinical primary endpoint, PASI-75 response at week 12, favored BMS-986322 over placebo based on the reported rates, although statistical significance was not reported in the registry.
Reported efficacy
Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks); Number of Participants With Safety Related Events (approximately 85 days); Number of Participants With TEAE by Worst Intensity (approximately 5 months); Number of Participants With AE Indicating Clinical Laboratory Abnormality (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in ECG Evaluations. (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Evaluations (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Evaluations (approximately 5 months): Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks): BMS-986322 16 mg 47.8% (95% CI 26.8 to 69.4) | BMS-986322 32 mg 80.8% (95% CI 60.6 to 93.4) | BMS-986322 64 mg 63% (95% CI 42.4 to 80.6) vs Placebo 3.6% (95% CI 0.1 to 18.3) (met)
Result source: NCT05730725
TQH3906
Developed by Sino Biopharmaceutical
NCT06542614 · Phase 2 · completed
This Phase 2 trial randomly assigned 209 people with plaque psoriasis to TQH3906 or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was the proportion reaching PASI 75, a 75% improvement in psoriasis severity, at week 12. The sponsor reports more than 90% reaching PASI 75 and more than 70% reaching PASI 90 at the recommended dose, but gives no placebo figure and no statistical comparison, so the size of the advantage over placebo is not established by what has been released.
Next expected readout: September 2027 · NCT07724366 (registry estimate)
Reported efficacy
Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 at week 12 (Up to week 12): At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks (met)
Result source: NCT06542614
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lomedeucitinib | TQH3906 |
|---|---|---|
| PASI 75 | 63% vs 3.6%+59.4 vs placeboNCT0573072517 other results
| —Trial running · NCT07724366 |
| PASI 90 | 40.7% vs 3.6%+37.1 vs placeboNCT0573072517 other results
| —Trial running · NCT07724366 |
| PASI 100 | 3.7% vs 0%+3.7 vs placeboNCT0573072517 other results
| —Trial running · NCT07724366 |
| sPGA 0/1 | 55.6% vs 3.6%+52 vs placeboNCT057307252 other results
| —Trial running · NCT07724366 |
| DLQI, change | —Not reported | —Trial running · NCT07724366 |
PASI 75
- Lomedeucitinib
- 63% vs 3.6%+59.4 vs placeboNCT05730725
17 other results
- 80.8% vs 3.6% NCT05730725
- 47.8% vs 3.6% NCT05730725
- 72% vs 4.2% NCT05730725
- 57.7% vs 4% NCT05730725
- 30.8% vs 3.6% NCT05730725
- 4% vs 0% NCT05730725
- 3.8% vs 0% NCT05730725
- 80.8% vs 4.2% NCT05730725
- 66.7% vs 4% NCT05730725
- 33.3% vs 3.6% NCT05730725
- 11.5% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 54.5% vs 4.2% NCT05730725
- 40% vs 4% NCT05730725
- 7.4% vs 3.6% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- TQH3906
- —Trial running · NCT07724366
PASI 90
- Lomedeucitinib
- 40.7% vs 3.6%+37.1 vs placeboNCT05730725
17 other results
- 48% vs 4.2% NCT05730725
- 30.8% vs 4% NCT05730725
- 7.7% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 61.5% vs 3.6% NCT05730725
- 61.5% vs 4.2% NCT05730725
- 25.9% vs 4% NCT05730725
- 18.5% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 13% vs 3.6% NCT05730725
- 13.6% vs 4.2% NCT05730725
- 8% vs 4% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- TQH3906
- —Trial running · NCT07724366
PASI 100
- Lomedeucitinib
- 3.7% vs 0%+3.7 vs placeboNCT05730725
17 other results
- 4% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 15.4% vs 0% NCT05730725
- 15.4% vs 0% NCT05730725
- 3.7% vs 0% NCT05730725
- 3.7% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- TQH3906
- —Trial running · NCT07724366
sPGA 0/1
- Lomedeucitinib
- 55.6% vs 3.6%+52 vs placeboNCT05730725
2 other results
- 69.2% vs 3.6% NCT05730725
- 54.2% vs 3.6% NCT05730725
- TQH3906
- —Trial running · NCT07724366
DLQI, change
- Lomedeucitinib
- —Not reported
- TQH3906
- —Trial running · NCT07724366
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lomedeucitinib: 3 of 4 rows · TQH3906: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lomedeucitinib |
|---|---|
| Dropout rate | 7.4%BMS-986322 64 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more results3.7%BMS-986322 32 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 3.7%BMS-986322 16 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 |
| Discontinued due to AEs | —BMS-986322 64 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more results—BMS-986322 32 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 —BMS-986322 16 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 |
| Serious AEs | 0%BMS-986322 64 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more results0%BMS-986322 32 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 3.7%BMS-986322 16 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 |
| Most frequent reported AEs | acne 14.8% (placebo 0%) covid-19 11.1% (placebo 0%) dermatitis acneiform 7.4% (placebo 0%) NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more resultsaphthous ulcer 11.1% (placebo 0%) folliculitis 11.1% (placebo 0%) upper respiratory tract infection 7.4% (placebo 0%) NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 diarrhoea 7.4% (placebo 0%) headache 7.4% (placebo 0%) influenza 7.4% (placebo 3.6%) NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lomedeucitinib
show 17 more results
show 2 more results
show 17 more results
show 17 more results
show 17 more results
show 14 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lomedeucitinib's landscape · TQH3906's landscape